Buscar
Mostrando ítems 1-10 de 54
Prevention of bleeding in hemophilia patients with high-titer inhibitors
(Expert Reviews, 2015-06-01)
Inhibitor development is the most serious adverse event linked to the treatment of hemophilia, as it renders standard hemostatic therapy ineffective. Consequently, inhibitor patients are at increased risk for difficult-to-control ...
Hemostatic changes and clinical sequelae after on-pump compared with off-pump coronary artery bypass surgery: a prospective randomized study
(LIPPINCOTT WILLIAMS & WILKINS, 2009)
Objective To delineate the effects of extracorporeal bypass on biomarkers of hemostasis, fibrinolysis, and inflammation and clinical sequelae. Methods Patients were assigned prospectively and randomly to either on-pump ...
Surgery in patients with hemophilia: Is thromboprophylaxis mandatory?
(Pergamon-elsevier Science LtdOxfordInglaterra, 2012)
T-kininogen, a cystatin-like molecule, inhibits ERK-dependent lymphocyte proliferation
(ELSEVIER, 2005-12)
Plasma levels of kininogens increase with age in both rats and humans. Kininogens are inhibitors of cysteine proteinases, and filarial cysteine proteinase inhibitors (cystatins) reduce the proliferation of T cells. We ...
Modulation of Double-Stranded RNA-Activated Protein Kinase in Insulin Sensitive Tissues of Obese Humans
(Wiley-blackwellHobokenEUA, 2013)
Encapsulação de luteína e avaliação in vitro da atividade da enzima acetilcolinesterase
(Universidade Tecnológica Federal do ParanáCampo MouraoBrasilDepartamento Acadêmico de AlimentosEngenharia de AlimentosUTFPR, 2017-11-30)
The causes of Alzheimer’s (AD) disease have been the subject of intense investigation. At present, search by new medicine and treatments become important. This way, the lutein showed possible candidate to act as a medicine ...
Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors
(2014)
In Mexico, 15% of haemophilia A (HA) patients develop inhibitory alloantibodies in response to replacement therapy with factor VIII (FVIII), requiring bypass therapy such as activated prothrombin complex concentrate (APCC). ...
Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors
(2014)
In Mexico, 15% of haemophilia A (HA) patients develop inhibitory alloantibodies in response to replacement therapy with factor VIII (FVIII), requiring bypass therapy such as activated prothrombin complex concentrate (APCC). ...